Anaplan has raised close to $264m in its flotation on the New York Stock Exchange that provided exits for Salesforce and Workday.

The Pfizer and Gilead-backed immuno-oncology therapy developer, which had raised $300m in an April series A round, floated at the top of its range.

The UCL Technology Fund is in line for an exit from gene therapy developer Orchard Therapeutics, which has raised more than $290m in equity funding.

The SoftBank-backed precision oncology test developer floated above its range and saw its share price rise 69% on the first day of trading.

The SIG China-backed mobile app developer raised $52.2m despite floating at the bottom of the IPO's range.

Liulishuo has listed on the New York Stock Exchange following a $71.9m initial public offering that provided an exit to publishing house Hearst.

The Eli Lilly-backed immuno-oncology product developer floated at the top of its range, with Bluebird Bio investing $10m.

Immunotherapy developer Sutro Biopharma has floated on the Nasdaq Global Market, providing exits for Merck & Co, Celgene, Amgen and Eli Lilly.

The lending platform's existing shareholders, which include Rocket Internet, sold $184m in shares as part of the offering.

The underwriters for the initial public offering have bought another $27m in shares in the Alphabet and Salesforce-backed online survey platform developer.